文献速递肿瘤 PET/CT

双示踪PET/CT揭示前列腺同时性肉瘤样癌与腺癌摄取差异

Divergent PET Tracer Avidity in Synchronous Sarcomatoid Carcinoma With Osteosarcomatous Differentiation and Adenocarcinoma of the Prostate: Insights From Dual-Tracer 68 Ga-PSMA and 18 F-FDG PET/CT Imaging.
PubMed 文献 · Clin Nucl Med · 2026-06-17

本文报道一名76岁、PSA轻度升高(5.44ng/mL)且mpMRI显示PI-RADS 5病灶的男性患者,接受68Ga-PSMA与18F-FDG双示踪PET/CT检查。68Ga-PSMA PET/CT显示一侧前列腺叶局灶性浓聚,18F-FDG PET/CT显示对侧叶高摄取;组织病理证实同时性高级别前列腺腺癌(Gleason 9)与伴骨肉瘤样分化的肉瘤样癌。该双示踪摄取不一致模式提示PSMA与FDG PET/CT在检出分子学异质性同时性前列腺恶性肿瘤方面具有互补作用。

要点

  • 前列腺同时性多种恶性肿瘤可表现为PSMA与FDG摄取不一致。
  • 双示踪PET/CT有助于发现分子学异质性的同时性前列腺病灶。
  • 病理证实腺癌(Gleason 9)与伴骨肉瘤样分化的肉瘤样癌共存。

核心结论

  • 双示踪68Ga-PSMA与18F-FDG PET/CT摄取不一致,可反映前列腺同时性恶性肿瘤的分子学差异,两者具有互补价值。

研究设计与样本

  • 单例病例报告:76岁男性,PSA 5.44ng/mL,mpMRI示PI-RADS 5病灶,行双示踪PET/CT并有组织病理证实。

主要发现

  • 68Ga-PSMA PET/CT示一侧前列腺叶局灶性浓聚,18F-FDG PET/CT示对侧叶高摄取。
  • 组织病理证实同时性高级别前列腺腺癌(Gleason 9)与伴骨肉瘤样分化的肉瘤样癌。

临床怎么用

  • 对怀疑前列腺多灶或异质性恶性肿瘤者,可考虑PSMA与FDG双示踪PET/CT以互补检出不同分子表型病灶。

局限性

  • 为单例病例报告,结论的外推需更多病例验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 76-year-old man with mildly elevated prostate-specific antigen (PSA, 5.44ng/mL) and a PI-RADS 5 lesion on multiparametric MRI underwent dual-tracer PET/CT. 68 Ga-PSMA PET/CT revealed focal intense uptake in one prostatic lobe, while 18 F-FDG PET/CT demonstrated avid uptake in the contralateral lobe. Histopathology confirmed synchronous high-grade prostatic adenocarcinoma (Gleason 9) and sarcomatoid carcinoma with osteosarcomatous differentiation. This discordant dual-tracer pattern highlights the complementary role of PSMA and FDG PET/CT in detecting molecularly divergent synchronous prostatic malignancies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ibrahim EA, Alper E. Divergent PET Tracer Avidity in Synchronous Sarcomatoid Carcinoma With Osteosarcomatous Differentiation and Adenocarcinoma of the Prostate: Insights From Dual-Tracer 68 Ga-PSMA and 18 F-FDG PET/CT Imaging. Clin Nucl Med. 2026. PMID: 42302393. doi:10.1097/RLU.0000000000006576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。